Working with ICER, or around it, on cost-effectiveness estimates
ADOBE
An ICER announcement that it will review a new drug can make drugmakers and patient groups worry. There are ways to work with ICER — and alternatives to it.
Suscribirse a:
Enviar comentarios (Atom)
No hay comentarios:
Publicar un comentario